A medicine to improve appetite for advanced lung cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is stage IV non-small cell lung cancer that has spread, and it is not the squamous cell type.
- You have not had chemotherapy for this cancer before.
- Your tumor does not have a 'driver gene' change that could be treated with targeted therapy.
- You are able to care for yourself (performance status 0-2) and are expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.
This study is testing whether a medication called megestrol acetate (a type of hormone that can boost appetite and help with weight gain) can improve outcomes for people with advanced non-small cell lung cancer who are malnourished. It is used as part of first-line treatment, meaning before any chemotherapy for the advanced cancer.
This study tests whether adding a drug that boosts appetite and weight to standard lung cancer treatment helps people with advanced small cell lung cancer who are experiencing weight loss and poor appetite. It aims to improve quality of life and treatment outcomes.
This study tests a new form of megestrol acetate (a medication that helps stimulate appetite and weight gain) for people with advanced liver cancer who are experiencing weight loss or loss of appetite. It is given alongside standard treatments for liver cancer, and the goal is to see if it can improve appetite and quality of life.
This trial tests a drug called megestrol acetate to help people with advanced lung cancer who are losing weight or have poor appetite. It aims to improve nutrition and quality of life.
This study tests a new form of megestrol, a medicine that helps stimulate appetite and promote weight gain, in people with advanced non-small cell lung cancer who are starting their first chemotherapy and are at risk of malnutrition. The goal is to see if it improves nutrition and overall well-being during treatment.
Hear when a new Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.